An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Xerix Announces Results of Once-Weekly Subcutaneous Hypothyroidism Therapy On May 30, Xeris Biopharma Holdings, Inc., announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s...
What do podcasting, grant writing, microaggressions, and retirement all have in common? They are all topics covered by new Professional Development Workshops at ENDO 2024! When attendees descend on Boston in June for ENDO 2024, they will have the opportunity to participate in a series of workshops that will enhance their visibility in the endocrine...
Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...
Winners Announced for the Endocrine Society’s 2024 Endocrine Images Art Competition
The Endocrine Society is delighted to announce that Lily Ng, PhD, and Douglas Forrest, PhD, have won the Society’s 2024 Endocrine Images Art Competition for their image of the astrocyte cell that expresses type 2 deiodinase. Now in its third year, the Art Competition celebrates the beauty of endocrine science as seen through the lens...
Good Vibrations: A New FDA-Approved Device Could Offer a Solution for Osteopenia Treatment
In a first for the treatment of osteopenia, the Osteoboost — a wearable device that delivers precise vibrations to the spine and hips — promises to offer a new form of therapy for clinicians treating postmenopausal women dealing with a loss of bone density. At the beginning of 2024, the U.S. Food and Drug...
The Joy of Endocrinology: Joy Y. Wu, MD, PhD, Breaks the Glass and Bamboo Ceilings